Two EACR Sustaining Members have announced a new agreement to encourage greater collaboration among researchers using Next-Generation Sequencing (NGS) technology.
Thermo Fisher Scientific and Illumina, Inc. announced earlier this week that they have signed a commercial agreement that enables Illumina to sell Thermo Fisher's Ion AmpliSeq technology to researchers who conduct scientific studies on Illumina’s next-generation sequencing platforms. Ion AmpliSeq technology is used to capture DNA and RNA from minute amounts of samples for application in multiple areas of research.
“Thermo Fisher expects standardization on the AmpliSeq technology will have a profound impact on disease research and encourage greater collaboration among the NGS community” said Joydeep Goswami, President of Clinical Next-Generation Sequencing and Oncology for Thermo Fisher Scientific.
Under the agreement, Thermo Fisher will provide Illumina with Ion AmpliSeq technology for research use. Illumina will sell the product directly to its customers under the name AmpliSeq for Illumina.
The agreement enables Illumina customers to utilize targeted resequencing as a follow-up to larger-scale exome and whole genome discovery studies. Ultimately, the agreement supports both organizations’ commitment to drive scientific advancement in human disease research by providing complete NGS workflow solutions.
“By expanding access to AmpliSeq chemistry to existing customers, we are enabling them to do even more with their systems” said Mark Van Oene, Chief Commercial Officer for Illumina.
This is considered an out of date browser. This website has been developed with modern browsers in mind to allow it to display at its best in a wide variety of viewing situations - including mobile viewing. But we haven't supported older browsers like IE8. Please upgrade to the latest version of Internet Explorer - or try Mozilla Firefox or Google Chrome. Both are excellent browsers.